By proceeding, you agree to our Terms of Use and Privacy Policy.
With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.
Meet translational and clinical experts from Roche, University of Pittsburgh, BMS, F-STAR, to discuss the various developments in LAG-3 research.
Find latest discussions on topics like issues faced in bispecific antibody-based approaches, enhancing combination therapy regimens and more.
Network with CXOs, Directors, Managers and Scientists to study more about LAG-3 combinations as immune checkpoint inhibitors!
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.